Hims & Hers推出了一款价值49美元的类似Wegovy的药物，引发了诺和诺德关于知识产权的法律威胁，并引发了安全隐忧。 Hims & Hers launched a $49 Wegovy-like drug, triggering Novo Nordisk’s legal threat over IP and sparking safety concerns.

《Hims & hers》推出了49版减重药物Wegovy,促使Novo Nordisk威胁就知识产权采取法律行动。 Hims & Hers has launched a $49 version of the weight-loss drug Wegovy, prompting Novo Nordisk to threaten legal action over intellectual property rights. 该公司的版本是一种复合配方,而不是经核准的通用配方,引起了对安全和监管合规的关切。 The company's version is a compounded formulation, not an approved generic, raising concerns about safety and regulatory compliance. 这一举动扰乱了市场,导致诺沃·诺迪斯克的股票下降。 The move has disrupted the market, causing Novo Nordisk's stock to drop.